1 min read
Add as a preferred source on GoogleBeam Therapeutics Reports Positive Topline Data From Sickle Cell Trial
The Phase 1/2 BEACON study met its primary efficacy endpoint and all primary safety endpoints at an interim analysis.
Beam Therapeutics announced positive topline results from its BEACON Phase 1/2 trial of ristoglogene autogetemcel (risto-cel), a cell therapy for sickle cell disease.
At an interim analysis, the study met its primary efficacy endpoint and all primary safety endpoints. Beam characterized the findings as positive topline data.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.